MK-4621

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Advanced Solid Tumors

Phase 1

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

TerminatedNCT03065023

Merck Sharp & Dohme LLCAdvanced Solid Tumors

Start: 2017-04-25End: 2018-05-18Updated: 2019-07-30

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

TerminatedNCT03739138

Merck Sharp & Dohme LLCAdvanced Solid Tumors

Start: 2018-12-18End: 2021-03-02Updated: 2022-02-28

Related Papers

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

2022-05-2127 citations

794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors

2020-11-014 citations

RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade

Blood2019-11-133 citations